COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 2 for:    macitentan | Fontan-palliated
Previous Study | Return to List | Next Study

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects (RUBATO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03153137
Recruitment Status : Recruiting
First Posted : May 15, 2017
Last Update Posted : March 18, 2020
Information provided by (Responsible Party):

Brief Summary:
The primary objective is to assess the effect of macitentan 10 mg as compared to placebo on exercise capacity through cardiopulmonary exercise testing.

Condition or disease Intervention/treatment Phase
Congenital Heart Disease Drug: Macitentan 10 mg Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 134 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Adult and Adolescent Subjects
Actual Study Start Date : August 14, 2017
Estimated Primary Completion Date : June 11, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Macitentan

Arm Intervention/treatment
Experimental: Macitentan
Macitentan 10 mg per day; film-coated tablet; oral use
Drug: Macitentan 10 mg
film-coated tablet; oral use

Placebo Comparator: Placebo
film-coated tablet; oral use
Drug: Placebo
film-coated tablet; oral use

Primary Outcome Measures :
  1. Change in peak VO2 (oxygen uptake) [ Time Frame: 16 weeks, i.e. from Baseline (Randomization/Visit 2) to Week 16 (Visit 4) ]
    Change in peak VO2 (oxygen uptake)

Secondary Outcome Measures :
  1. Change in peak VO2 [ Time Frame: 52 weeks, i.e. from Baseline (Visit 2) over 52 weeks ]
    Change in peak VO2

  2. Physical activity measured by accelerometer [ Time Frame: 16 weeks, i.e. from Baseline (Visit 2) to Week 16 (Visit 4) ]
    Change in mean count per minute of daily physical activity measured by accelerometer

  3. Treatment-emergent AEs and SAEs [ Time Frame: at least 52 weeks, i.e. up to 30 days after study treatment discontinuation ]
    Treatment-emergent AEs and SAEs

  4. Trough (pre dose) plasma concentrations [ Time Frame: at Week 8 (Visit 3) and Week 16 (Visit 4): 2 days OR at EOT in the case of premature study drug discontinuation: 1 day ]
    Trough (pre dose) plasma concentrations

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent/assent from the subject and/or a legal representative prior to initiation of any study-mandated procedures
  • Fontan-palliated subjects with either intra-atrial lateral tunnel total cavopulmonary connection (LT-TCPC), or extra cardiac tunnel TCPC (EC-TCPC) surgery > 1 year before Screening. Either LT- or EC-TCPC can be primary or secondary to atrio-pulmonary connection
  • New York Heart Association (NYHA) functional class (FC) II or III (assessed by the investigator using the Specific Activity Scale
  • Women of childbearing potential must have a negative serum pregnancy test use reliable contraception

Exclusion Criteria:

  • Pattern of Fontan circulation severity
  • Deterioration of the Fontan-palliated condition.
  • Limitations to Cardiopulmonary exercise testing (CPET)
  • Peak VO2 < 15 mL/kg/min.
  • Any known factor or disease that may interfere with treatment compliance or full participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03153137

Layout table for location contacts
Contact: Study Contact 844-434-4210

Show Show 58 study locations
Sponsors and Collaborators

Additional Information:
Layout table for additonal information
Responsible Party: Actelion Identifier: NCT03153137    
Other Study ID Numbers: AC-055H301
2016-003320-23 ( EudraCT Number )
First Posted: May 15, 2017    Key Record Dates
Last Update Posted: March 18, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Cardiovascular Diseases
Endothelin A Receptor Antagonists
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Endothelin B Receptor Antagonists